Similarly, the median PFS of 8.1 months with divarasib observed in this trial is the longest reported for a KRAS G12C inhibitor combined with an EGFR inhibitor in patients with CRC (5.6 months (95% CI: 4.2, 6.3) with sotorasib plus panitumumab and 6.9 months (95% CI: 5.4, 8.1) for adagrasib plus cetuximab)17,20. The gene discussed is KRAS; the disease is colorectal carcinoma.